+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Blood Cancer Drug"

From
From
From
Hematological Malignancies - Global Strategic Business Report - Product Thumbnail Image

Hematological Malignancies - Global Strategic Business Report

  • Report
  • April 2025
  • 193 Pages
  • Global
From
From
From
From
Blood Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Blood Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
T-Cell Blood Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

T-Cell Blood Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more